Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Armata Pharmaceuticals Inc

Healthcare US ARMP

7.35USD
0.34(4.85%)

Last update at 2026-06-24T17:48:00Z

Day Range

6.517.35
LowHigh

52 Week Range

1.1714.88
LowHigh

Fundamentals

  • Previous Close 7.01
  • Market Cap542.17M
  • Volume89449
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-29.69100M
  • Revenue TTM4.90M
  • Revenue Per Share TTM0.14
  • Gross Profit TTM -10.81300M
  • Diluted EPS TTM-4.8

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -173.79900M -18.91600M -69.04500M -36.91700M -23.15500M
Minority interest - - - - -
Net income -173.79900M -18.91600M -69.04500M -36.88800M -23.21900M
Selling general administrative 12.41M 13.18M 11.65M 7.44M 8.28M
Selling and marketing expenses - - 0.97M - -
Gross profit 3.37M -29.25200M 3.56M - -
Reconciled depreciation 1.53M 1.32M 0.92M 0.89M 1.17M
Ebit -31.22200M -42.43600M -66.41900M -36.94600M -23.82200M
Ebitda -29.69100M -41.11100M -65.44700M -36.05400M -22.64800M
Depreciation and amortization 1.53M 1.32M 0.97M 0.89M 1.17M
Non operating income net other - - - 0.03M 0.67M
Operating income -31.22200M -42.43600M -40.89000M -36.94600M -23.82200M
Other operating expenses 36.13M 47.61M 45.42M 36.95M 23.82M
Interest expense 16.59M 10.74M 2.63M 0.03M 0.06M
Tax provision - - - - -
Interest income 0.39M 0.70M 0.12M 0.03M 0.00500M
Net interest income -16.20200M -10.04500M -1.05100M 0.03M -0.05900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -0.02900M 0.06M
Total revenue 4.90M 5.17M 4.53M 0.00000M 4.47M
Total operating expenses 34.59M 13.18M 44.45M 36.95M 23.82M
Cost of revenue 1.53M 34.43M 0.97M - -
Total other income expense net -142.57700M 23.52M -28.15500M 0.03M 0.67M
Discontinued operations - - - - -
Net income from continuing ops -173.79900M -18.91600M -59.51200M -36.91700M -23.15500M
Net income applicable to common shares - - - -36.91700M -23.15500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 76.88M 86.44M 98.36M 95.83M 69.77M
Intangible assets 10.26M 10.26M 10.26M 10.26M 10.26M
Earning assets - - - - -
Other current assets 1.51M 1.27M 2.27M 10.26M 4.71M
Total liab 295.48M 134.46M 130.43M 59.75M 44.37M
Total stockholder equity -218.59600M -48.01900M -32.06500M 36.08M 25.40M
Deferred long term liab - - - 10.26M 10.26M
Other current liab 3.46M 4.10M -4.08600M 6.18M 2.17M
Common stock 0.36M 0.36M 0.36M 0.36M 0.27M
Capital stock 0.36M 0.36M 0.36M 0.36M 0.27M
Retained earnings -501.53400M -327.73500M -308.81900M -239.77400M -202.85700M
Other liab - - - 3.08M 3.08M
Good will 3.49M 3.49M 3.49M 3.49M 3.49M
Other assets - - - 18.64M 13.21M
Cash 8.69M 9.29M 13.52M 14.85M 10.29M
Cash and equivalents - - - - -
Total current liabilities 8.95M 48.25M 16.46M 24.87M 4.81M
Current deferred revenue - - -5.37700M - -
Net debt 279.33M 117.22M 106.85M 33.96M 27.70M
Short term debt 4.56M 43.38M 18.96M 17.01M 1.51M
Short long term debt - 38.95M - - -
Short long term debt total 288.02M 126.52M 120.37M 48.81M 37.99M
Other stockholder equity 282.57M 279.35M 276.39M 275.49M 227.98M
Property plant equipment - - - 3.62M 2.22M
Total current assets 10.67M 11.31M 19.15M 27.05M 14.99M
Long term investments - - - - -
Net tangible assets - - - 22.33M 11.65M
Short term investments - - - - -
Net receivables 0.47M 0.74M 3.36M 1.94M 2.99M
Long term debt 256.92M 55.44M 82.31M - -
Inventory - - - - -2.98900M
Accounts payable 0.92M 0.77M 1.58M 1.68M 1.14M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 0.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.36M 0.27M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -239.77400M -202.85700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.97M 0.97M 8.19M 8.39M 2.96M
Deferred long term asset charges - - - - -
Non current assets total 66.21M 75.13M 79.21M 68.79M 54.77M
Capital lease obligations 31.10M 32.12M 38.06M 48.81M 37.99M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -1.87900M -5.28900M -2.21100M -1.30400M
Change to liabilities - - - 3.67M 0.18M
Total cashflows from investing activities -0.54200M -1.87900M -8.13400M -2.21100M -1.30400M
Net borrowings 25.00M 34.89M 54.03M -0.50000M -
Total cash from financing activities 25.61M 34.96M 53.99M 44.02M 25.52M
Change to operating activities - - - -3.22600M -3.40700M
Net income -173.79900M -18.91600M -69.04500M -36.91700M -23.15500M
Change in cash -0.69300M -4.47200M -1.56900M 9.32M 0.64M
Begin period cash flow 14.77M 19.24M 20.81M 11.49M 10.85M
End period cash flow 14.08M 14.77M 19.24M 20.81M 11.49M
Total cash from operating activities -25.76300M -37.55100M -47.42300M -32.48100M -23.57500M
Issuance of capital stock - - 0.00000M 44.39M 26.32M
Depreciation 1.53M 1.32M 0.97M 0.89M 1.17M
Other cashflows from investing activities - - 0.01000M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - -0.04300M 44.52M 26.93M
Other cashflows from financing activities -0.04600M -0.06100M -0.04300M -0.37500M -0.80100M
Change to netincome - - - 3.90M 3.41M
Capital expenditures 0.54M 1.88M 8.14M 2.21M 1.30M
Change receivables - - - - -
Cash flows other operating - - - -4.01900M -5.18700M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 9.32M 0.64M
Change in working capital -1.41200M -2.09900M -9.64600M 0.44M -3.22300M
Stock based compensation 2.61M 2.89M 0.94M 3.10M 2.88M
Other non cash items 145.31M -20.75400M 29.36M - 0.06M
Free cash flow -26.30500M -39.43000M -55.56700M -34.69200M -24.87900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARMP
Armata Pharmaceuticals Inc		 0.34 4.85% 7.35 - - 110.56 2.11 198.54 14.44
NVO
Novo Nordisk A/S		 0.03 0.05% 47.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.16 2.48% 48.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.92 1.28% 625.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.

Armata Pharmaceuticals Inc

5005 McConnell Avenue, Los Angeles, CA, United States, 90066

Key Executives

Name Title Year Born
Dr. Brian Varnum Ph.D. CEO & Director 1960
Mr. Todd R. Patrick MBA Advisor 1963
Mr. Steven R. Martin Advisor 1961
Dr. Wenyuan Shi Ph.D. Co-Founder & Founding Scientist NA
Ms. Erin Butler Principal Financial & Accounting Officer and VP of Fin. & Admin. NA
Mr. Duane Alfred Morris BA VP of Operations 1950
Dr. Mina Pastagia M.D., MS Sr. VP of Clinical Devel. NA
Dr. Deborah L. Birx M.D. CEO & Director 1957
Dr. Mina Pastagia M.D., MS Chief Medical Officer 1975
Mr. David House Senior VP of Finance & Principal Financial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions